E-Mail
IMAGE: Ludwig Memorial Sloan Kettering s investigators Taha Merghoub, Jedd Wolchok and assistant attending physician Andrew Chow. view more
Credit: Ludwig Cancer Research
JUNE 10, 2021, NEW YORK - A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system s cancer-killing CD8+ T cells.
Reported in the current issue of
Cancer Cell and led by Ludwig investigators Taha Merghoub and Jedd Wolchok at Memorial Sloan Kettering (MSK) and Charles Rudin of MSK, the study shows that cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), a molecule that they surprisingly found on the surface of highly activated, cytotoxic and proliferative CD8+ T-cells.
E-Mail
IMAGE: Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi view more
Credit: Ludwig Cancer Research
FEBRUARY 15, 2021, NEW YORK - A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis.
Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi now at Weill Cornell Medicine have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system. In such tumors, anti-CTLA-4 therapy also destabilizes and reprograms regulatory T